These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6352647)

  • 1. Ceftazidime in cystic fibrosis: clinical, microbiological and immunological studies.
    Cullen RT; McCrae WM; Govan J; Raeburn JA; Ingram TM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():369-75. PubMed ID: 6352647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime - a significant advance in the treatment of cystic fibrosis.
    David TJ; Phillips BM; Connor PJ
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():337-40. PubMed ID: 6352639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with ceftazidime in cystic fibrosis.
    Dodge J; Zamiri I; Goodchild M; Ingram P
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():325-9. PubMed ID: 6352637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia.
    Gold R; Jin E; Levison H; Isles A; Fleming PC
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():331-6. PubMed ID: 6352638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis.
    Strandvik B; Malmborg AS; Alfredson H; Ericsson A
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():283-7. PubMed ID: 6352633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime treatment of chronic Pseudomonas infection in patients with cystic fibrosis.
    Fluge G; Digranes A; Michalsen H; Stiris T; Bergan T; Qvigstad EK
    Eur J Respir Dis; 1987 Oct; 71(4):239-43. PubMed ID: 3319661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.
    Mastella G; Agostini M; Barlocco G; Bonomi U; Borgo G; Bozzino L; Cabrini G; Cappelletti LM; Castellani L; Conforti M
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():297-311. PubMed ID: 6311788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis.
    Permin H; Koch C; Høiby N; Christensen HO; Møller AF; Møller S
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():313-23. PubMed ID: 6352636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.
    Kercsmar CM; Stern RC; Reed MD; Myers CM; Murdell D; Blumer JL
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():289-95. PubMed ID: 6352634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open study of the use of ceftazidime in Gram-negative infections.
    Wardle JK; Snow MH; Ingham HR; Selkon JB
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():389-93. PubMed ID: 6352650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of ceftazidime in paediatrics.
    Assael BM; Boccazzi A; Caccamo ML; Giunta A; Marini A; Padoan R; Rusconi F; Sereni F
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():341-6. PubMed ID: 6352640
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime.
    De Boeck K; Breysem L
    J Antimicrob Chemother; 1998 Mar; 41(3):407-9. PubMed ID: 9578170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.
    Byrne S; Maddison J; Connor P; Doughty I; Dodd M; Jenney M; Webb AK; David TJ
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():135-43. PubMed ID: 8543489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children.
    Rappaz I; Decosterd LA; Bille J; Pilet M; Bélaz N; Roulet M
    Eur J Pediatr; 2000 Dec; 159(12):919-25. PubMed ID: 11131352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria.
    Scully BE; Neu HC
    Arch Intern Med; 1984 Jan; 144(1):57-62. PubMed ID: 6419690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.
    Vinks AA; Brimicombe RW; Heijerman HG; Bakker W
    J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime therapy for serious infections.
    Bint AJ; Constable J; Patton KR; Constable FL
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():115-21. PubMed ID: 6352613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral anti-pseudomonal antibiotics for cystic fibrosis.
    Remmington T; Jahnke N; Harkensee C
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005405. PubMed ID: 17636796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa?
    Watkins J; Francis J; Kuzemko JA
    Scand J Gastroenterol Suppl; 1988; 143():81-5. PubMed ID: 3133756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins.
    Zobell JT; Waters CD; Young DC; Stockmann C; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Feb; 48(2):107-22. PubMed ID: 22949297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.